Clinical Trial Update: QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating QL1706 in combination with chemotherapy as neoadjuvant therapy for early high-risk estrogen receptor-positive, HER2-negative breast c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• QL1706

Snippet

Sponsor: Fudan University | Conditions: Early Breast Cancer, Neoadjuvant Therapy | Phase 2 | Status: NOT_YET_RECRUITING